NVCT
NVCT clinical trials: Nuvectis Pharma, Inc.
Every trial on ClinicalTrials.gov where Nuvectis Pharma, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 4
- Trials linked
- 4
- As lead sponsor
- 0
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
NVCT on the catalyst calendar · NVCT registry changes
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Mar 2027Sponsor estimate | NCT05873686A Phase 1 Clinical Study of NXP900 in Subjects With Advanced CancersNuvectis Pharma, Inc. · Advanced Solid Tumor | NVCTLead | Phase 1 | Active, not recruiting | Locked | Locked | Locked |
| Aug 2027Sponsor estimate | NCT07784959Study of NXP900 With Lorlatinib in ALK+ Lung CancerNuvectis Pharma, Inc. · ALK Positive | NVCTLead | Phase 1 | Recruiting | Locked | Locked | Locked |
| Jan 1, 2025Actual | NCT05226507A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian CancerNuvectis Pharma, Inc. · Advanced Solid Tumor | NVCTLead | Phase 1 | Terminated | Locked | Locked | Locked |
| Dec 2026Sponsor estimate | NCT07315113Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung CancerNuvectis Pharma, Inc. · EGFR Mutation Positive Non-small Cell Lung Cancer | NVCTLead | Phase 1 | Recruiting | Locked | Locked | Locked |
- Primary completion Mar 2027Sponsor estimatePhase 1NCT05873686A Phase 1 Clinical Study of NXP900 in Subjects With Advanced CancersNuvectis Pharma, Inc. · Advanced Solid TumorActive, not recruitingNVCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 2027Sponsor estimatePhase 1NCT07784959Study of NXP900 With Lorlatinib in ALK+ Lung CancerNuvectis Pharma, Inc. · ALK PositiveRecruitingNVCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 1, 2025ActualPhase 1NCT05226507A Phase 1 Clinical Study of NXP800 in Subjects With Advanced Cancers and Expansion in Subjects With Ovarian CancerNuvectis Pharma, Inc. · Advanced Solid TumorTerminatedNVCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 1NCT07315113Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung CancerNuvectis Pharma, Inc. · EGFR Mutation Positive Non-small Cell Lung CancerRecruitingNVCTLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 4 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner